Recursion Pharmaceuticals IncNASDAQ:RXRX
- LAST PRICE6.2650
- TODAY'S CHANGE (%)-0.6450 (-9.3343%)
- Bid / Lots6.2600/ 9
- Ask / Lots6.2700/ 18
- Open / Previous Close6.8900 / 6.9100
- Day Range
- 52 Week Range
- Volume6,071,967
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RXRX |
|---|---|---|
| 09:32 ET | 115313 | 6.86 |
| 09:33 ET | 91832 | 6.7324 |
| 09:35 ET | 104699 | 6.69 |
| 09:37 ET | 115840 | 6.66 |
| 09:39 ET | 107287 | 6.65 |
| 09:42 ET | 104548 | 6.62 |
| 09:44 ET | 108329 | 6.568 |
| 09:46 ET | 77023 | 6.6 |
| 09:48 ET | 136703 | 6.5388 |
| 09:50 ET | 130480 | 6.58 |
| 09:51 ET | 25755 | 6.57 |
| 09:53 ET | 73814 | 6.565 |
| 09:55 ET | 75854 | 6.56 |
| 09:57 ET | 31996 | 6.565 |
| 10:00 ET | 59413 | 6.53 |
| 10:02 ET | 59551 | 6.5275 |
| 10:04 ET | 140447 | 6.525 |
| 10:06 ET | 58570 | 6.48 |
| 10:08 ET | 88892 | 6.475 |
| 10:09 ET | 112100 | 6.47 |
| 10:11 ET | 28553 | 6.4635 |
| 10:13 ET | 37086 | 6.42 |
| 10:15 ET | 76671 | 6.41 |
| 10:18 ET | 91312 | 6.405 |
| 10:20 ET | 44188 | 6.385 |
| 10:22 ET | 30290 | 6.385 |
| 10:24 ET | 89925 | 6.375 |
| 10:26 ET | 75405 | 6.33 |
| 10:27 ET | 100675 | 6.37 |
| 10:29 ET | 93526 | 6.345 |
| 10:31 ET | 50969 | 6.36 |
| 10:33 ET | 55580 | 6.355 |
| 10:36 ET | 56970 | 6.345 |
| 10:38 ET | 90801 | 6.325 |
| 10:40 ET | 37244 | 6.36 |
| 10:42 ET | 58816 | 6.3513 |
| 10:44 ET | 59131 | 6.345 |
| 10:45 ET | 60048 | 6.355 |
| 10:47 ET | 53300 | 6.3147 |
| 10:49 ET | 69200 | 6.34 |
| 10:51 ET | 51570 | 6.33 |
| 10:54 ET | 48203 | 6.3095 |
| 10:56 ET | 122137 | 6.275 |
| 10:58 ET | 61765 | 6.265 |
| 11:00 ET | 43423 | 6.29 |
| 11:02 ET | 32491 | 6.26 |
| 11:03 ET | 43078 | 6.29 |
| 11:05 ET | 55690 | 6.265 |
| 11:07 ET | 63719 | 6.285 |
| 11:09 ET | 41829 | 6.3059 |
| 11:12 ET | 20779 | 6.295 |
| 11:14 ET | 18493 | 6.3199 |
| 11:16 ET | 32154 | 6.36 |
| 11:18 ET | 26621 | 6.365 |
| 11:20 ET | 19023 | 6.3371 |
| 11:21 ET | 23596 | 6.37 |
| 11:23 ET | 21364 | 6.3877 |
| 11:25 ET | 26483 | 6.4 |
| 11:27 ET | 37273 | 6.4 |
| 11:30 ET | 20087 | 6.375 |
| 11:32 ET | 16645 | 6.36 |
| 11:34 ET | 7614 | 6.35 |
| 11:36 ET | 22907 | 6.36 |
| 11:38 ET | 26123 | 6.38 |
| 11:39 ET | 269359 | 6.45 |
| 11:41 ET | 35357 | 6.455 |
| 11:43 ET | 18015 | 6.4276 |
| 11:45 ET | 16492 | 6.45 |
| 11:48 ET | 19062 | 6.46 |
| 11:50 ET | 39137 | 6.435 |
| 11:52 ET | 53504 | 6.4 |
| 11:54 ET | 71352 | 6.4168 |
| 11:56 ET | 23844 | 6.44 |
| 11:57 ET | 59821 | 6.43 |
| 11:59 ET | 23481 | 6.4051 |
| 12:01 ET | 40214 | 6.43 |
| 12:03 ET | 39803 | 6.385 |
| 12:06 ET | 54669 | 6.36 |
| 12:08 ET | 53630 | 6.315 |
| 12:10 ET | 26489 | 6.325 |
| 12:12 ET | 61179 | 6.305 |
| 12:14 ET | 26463 | 6.275 |
| 12:15 ET | 22459 | 6.275 |
| 12:17 ET | 55168 | 6.28 |
| 12:19 ET | 38794 | 6.29 |
| 12:21 ET | 22086 | 6.2853 |
| 12:24 ET | 60000 | 6.265 |
| 12:26 ET | 42794 | 6.2853 |
| 12:28 ET | 28196 | 6.26 |
| 12:30 ET | 24987 | 6.2865 |
| 12:32 ET | 30006 | 6.275 |
| 12:33 ET | 20541 | 6.275 |
| 12:35 ET | 13795 | 6.2852 |
| 12:37 ET | 17896 | 6.275 |
| 12:39 ET | 13567 | 6.295 |
| 12:42 ET | 19928 | 6.295 |
| 12:44 ET | 25271 | 6.275 |
| 12:46 ET | 9641 | 6.2823 |
| 12:48 ET | 26259 | 6.275 |
| 12:50 ET | 50846 | 6.265 |
| 12:51 ET | 34208 | 6.265 |
Nov 13, 2024
Recursion and Exscientia Shareholders Approve the Proposed Combination, from 9:08AM ET on Wednesday Nov 13, 2024 by Dow Jones
9:08AM ET on Wednesday Nov 13, 2024 by Dow JonesPress Release: Recursion and Exscientia Shareholders Approve the Proposed Combination, from 9:08AM ET on Wednesday Nov 13, 2024 by Dow Jones
9:08AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden, from 4:54PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:54PM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 7, 2024
DJ Recursion Pharmaceuticals Price Target Maintained With a $11.00/Share by Needham, from 7:36AM ET on Thursday Nov 07, 2024 by Dow Jones
7:36AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results, from 4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:15PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Recursion Pharmaceuticals Inc | 2.0B | -4.1x | --- |
Nurix Therapeutics Inc | 1.9B | -8.3x | --- |
Akero Therapeutics Inc | 2.1B | -7.4x | --- |
Tarsus Pharmaceuticals Inc | 1.8B | -11.8x | --- |
Neumora Therapeutics Inc | 1.9B | -6.2x | --- |
Structure Therapeutics Inc | 2.2B | -15.6x | --- |
Company Information
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
Contact Information
- Headquarters
- 41S Rio Grande StreetSALT LAKE CITY, UT, United States 84101
- Phone
- 385-269-0203
- Fax
- 801-581-7895
Executives
- Independent Chairman of the Board
- Robert Hershberg
- President, Chief Operating Officer
- Tina Larson
- Chief Executive Officer, Director
- Christopher Gibson
- Chief Financial Officer
- Michael Secora
- Director, Chief Research and Development Officer, Chief Commercial Officer
- Najat Khan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0B |
|---|---|
Revenue (TTM) | $65.2M |
Shares Outstanding | 286.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.83 |
EPS | $-1.53 |
Book Value | $1.98 |
P/E Ratio | -4.1x |
Price/Sales (TTM) | 30.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -604.70% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
